Περίληψη:
In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Συγγραφείς:
Elaidi, R.
Harbaoui, A.
Beuselinck, B.
Eymard, J.-C.
Bamias, A.
De Guillebon, E.
Porta, C.
Vano, Y.
Linassier, C.
Debruyne, P.R.
Gross-Goupil, M.
Ravaud, A.
Aitelhaj, M.
Marret, G.
Oudard, S.
Λέξεις-κλειδιά:
axitinib; everolimus; pazopanib; protein tyrosine kinase inhibitor; sorafenib; sunitinib; temsirolimus; antineoplastic agent; MTOR protein, human; protein kinase inhibitor; protein tyrosine kinase; target of rapamycin kinase, adult; aged; Article; bone metastasis; cancer grading; cancer survival; cohort analysis; controlled study; drug treatment failure; female; Fuhrman grade; human; kidney carcinoma; major clinical study; male; metastatic clear cell renal cell carcinoma; metastatic clear cell renal cell carcinoma; priority journal; progression free survival; retrospective study; time to treatment; treatment duration; treatment outcome; antagonists and inhibitors; Carcinoma, Renal Cell; clinical trial; disease free survival; Kaplan Meier method; middle aged; mortality; multicenter study; procedures; proportional hazards model; salvage therapy; treatment outcome, Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Salvage Therapy; TOR Serine-Threonine Kinases; Treatment Outcome
